OraSure Technologies, Inc. (OSUR)
| Market Cap | 206.55M -7.7% |
| Revenue (ttm) | 113.02M -30.1% |
| Net Income | -75.07M |
| EPS | -1.05 |
| Shares Out | 68.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,389,243 |
| Open | 3.010 |
| Previous Close | 2.950 |
| Day's Range | 2.960 - 3.185 |
| 52-Week Range | 2.080 - 3.820 |
| Beta | 0.89 |
| Analysts | Hold |
| Price Target | 3.00 (0.0%) |
| Earnings Date | May 6, 2026 |
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid tes... [Read more]
Financial Performance
In 2025, OraSure Technologies's revenue was $115.02 million, a decrease of -38.10% compared to the previous year's $185.83 million. Losses were -$68.73 million, 252.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for OSUR stock is "Hold." The 12-month stock price target is $3.0, which is no change of 0.00% from the latest price.
News
OraSure Technologies Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 4% sequentially to $27.9 million, with gross margin expansion and strong diagnostics performance. Two FDA-cleared product launches are expected mid-year, supporting guidance for continued revenue growth and margin improvement.
OraSure Announces First Quarter 2026 Financial Results
BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its fin...
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certai...
OraSure Technologies Appoints John D. Bertrand to its Board of Directors
Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Techn...
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All...
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technol...
Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says
Activist investor Altai Capital Management called on OraSure Technologies to explore a sale, saying the medical device maker could fetch double its current share price, according to a letter seen by...
OraSure Technologies Earnings Call Transcript: Q4 2025
Q4 2025 revenue exceeded guidance, with stabilization in key markets and strong cash reserves. Two major product launches are planned for mid-2026, and manufacturing consolidation plus cost-saving actions are expected to drive margin improvement and growth.
OraSure to launch OraQuick HIV Self-Test in Canada
OraSure (OSUR) Technologies announced its OraQuick HIV Self-Test has received a license from Health Canada for use in Canada. The OraQuick HIV Self-Test is a point-of-care rapid antibody test. It…
OraSure to Launch OraQuick™ HIV Self-Test in Canada
BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today anno...
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certai...
OraSure confirms receipt of director nominations from Altai Capital
OraSure (OSUR) Technologies confirmed that Altai Capital has nominated two candidates, including the fund’s founder Rishi Bajaj, to stand for election to the company’s board at its 2026 Annual Meeting...
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
BETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, ...
Altai Capital Management nominates two candidates to OraSure board
Altai Capital Management, one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure (OSUR) Technologies, announced that it has nominated tw...
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technolog...
OraSure submits CT/NG molecular self-test, Colli-Pee device for FDA review
OraSure (OSUR) Technologies submitted two separate applications at the end of 2025 to the U.S. Food and Drug Administration for clearance of its rapid molecular self-test for Chlamydia trachomatis and...
OraSure confirms Altai Capital intent to nominate two board members
OraSure (OSUR) Technologies confirmed that Altai Capital has notified the company of its intent to nominate two candidates, including the fund’s founder, Rishi Bajaj, to stand for election to the…
OraSure Technologies Issues Statement Regarding Altai Capital's Intent to Nominate Director Candidates
BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, ...
Altai Capital announces intention to nominate two candidates for OraSure board
Altai Capital, one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure (OSUR), announced that it has delivered a letter notifying the…
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. (“Altai”), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technolog...
OraSure Technologies Transcript: Stephens Annual Investment Conference
The conference highlighted a robust innovation pipeline, including new molecular diagnostics and sample management products, with a focus on achieving profitability by 2027–2028. Strong cash reserves support ongoing investment and share buybacks, while diversification and operational efficiency are expected to drive growth and margin expansion.
OraSure to acquire BioMedomics, expanding diagnostic portfolio
OraSure (OSUR) announced it signed a definitive agreement to acquire BioMedomics. The company said the transaction expands its diagnostic portfolio by adding SickleSCAN, a rapid, point-of-need test fo...
OraSure Technologies Earnings Call Transcript: Q3 2025
Q3 revenue reached $27.1 million, with core revenue at $27.0 million and a GAAP gross margin of 43.5%. Guidance for Q4 is $25–$28 million, with 2025 as a transition year and growth expected in 2026. BioMedomics acquisition and innovation pipeline position the company for future expansion.
OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th
BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain...
OraSure Technologies Appoints Steven K. Boyd to its Board of Directors
Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective OraSure Board Has Added Three New Independent...